Research and experimental development on natural sciences and engineering
ARXX THERAPEUTICS AS
Revenue 2024
NOK 5.0m
Operating profit
NOK −66.8m
Equity
NOK 13.5m
Incorporated
2015
Share capital
NOK 5.5m
Roles
Regnskapsfører
Revisor
Styrets lederBerte Aagot Hedding Poulsson
StyremedlemMark William-Semrau Gaffney
StyremedlemJonas Hallén
Auditor
Auditor at related companies
None of the 1 related companies use the same auditor.
| Company | Auditor | |
|---|---|---|
| CALLUNA PHARMA AS | BJØRGVIN REVISJON AS | different |
Shareholders
| Name | Stake | Shares | Year |
|---|---|---|---|
| CALLUNA PHARMA AS | 100.0% | 26043511.000000 | 2025 |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.